- Home
- GALT
as of 02-10-2026 10:31am EST
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | NORCROSS |
| Market Cap: | 203.7M | IPO Year: | N/A |
| Target Price: | $8.50 | AVG Volume (30 days): | 322.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.59 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.12 - $7.13 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered GALT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Galectin Therapeutics Inc. (GALT)
Director
Avg Cost/Share
$2.70
Shares
300
Total Value
$810.00
Owned After
65,682
SEC Form 4
President and CEO
Avg Cost/Share
$3.58
Shares
37,698
Total Value
$134,853.29
Owned After
832,592
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$3.67
Shares
20,354
Total Value
$74,695.11
Owned After
7,614
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$3.65
Shares
21,446
Total Value
$78,204.98
Owned After
0
SEC Form 4
President and CEO
Avg Cost/Share
$3.91
Shares
27,731
Total Value
$108,342.24
Owned After
832,592
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$3.90
Shares
25,732
Total Value
$100,298.19
Owned After
7,614
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$3.90
Shares
25,499
Total Value
$99,407.85
Owned After
0
SEC Form 4
President and CEO
Avg Cost/Share
$4.20
Shares
18,571
Total Value
$77,938.77
Owned After
832,592
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$4.20
Shares
13,914
Total Value
$58,394.28
Owned After
7,614
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$4.20
Shares
13,055
Total Value
$54,789.22
Owned After
0
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| ELDRED KARY | GALT | Director | Feb 6, 2026 | Buy | $2.70 | 300 | $810.00 | 65,682 | |
| LEWIS JOEL | GALT | President and CEO | Jan 6, 2026 | Sell | $3.58 | 37,698 | $134,853.29 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Jan 6, 2026 | Sell | $3.67 | 20,354 | $74,695.11 | 7,614 | |
| Jamil Khurram | GALT | Chief Medical Officer | Jan 6, 2026 | Sell | $3.65 | 21,446 | $78,204.98 | 0 | |
| LEWIS JOEL | GALT | President and CEO | Jan 5, 2026 | Sell | $3.91 | 27,731 | $108,342.24 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Jan 5, 2026 | Sell | $3.90 | 25,732 | $100,298.19 | 7,614 | |
| Jamil Khurram | GALT | Chief Medical Officer | Jan 5, 2026 | Sell | $3.90 | 25,499 | $99,407.85 | 0 | |
| LEWIS JOEL | GALT | President and CEO | Jan 2, 2026 | Sell | $4.20 | 18,571 | $77,938.77 | 832,592 | |
| CALLICUTT JACK W | GALT | Chief Financial Officer | Jan 2, 2026 | Sell | $4.20 | 13,914 | $58,394.28 | 7,614 | |
| Jamil Khurram | GALT | Chief Medical Officer | Jan 2, 2026 | Sell | $4.20 | 13,055 | $54,789.22 | 0 |
Compare GALT vs Leading Stocks
See how GALT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "GALT Galectin Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.